Venrock Healthcare Capital Partners III L.P. 13D and 13G filings for KalVista Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 8:52 pm Purchase | 2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | Venrock Healthcare Capital Partners III L.P. | 4,824,731 14.000% | 1,251,017 (+35.01%) | Filing |
| 2023-12-28 4:16 pm Purchase | 2023-12-26 | 13G | KalVista Pharmaceuticals, Inc. KALV | Venrock Healthcare Capital Partners III L.P. | 3,573,714 10.300% | 657,047 (+22.53%) | Filing |
| 2023-01-09 4:06 pm Purchase | 2022-12-28 | 13G | KalVista Pharmaceuticals, Inc. KALV | Venrock Healthcare Capital Partners III L.P. | 2,916,667 8.600% | 2,916,667 (New Position) | Filing |